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Background: Hepatitis C virus (HCV) is an RNA virus which has been known to cause acute and chronic necro-
inflammatory disease of the liver. It is the leading cause of end-stage liver disease and hepatocellular carcinoma.
HIV is known to have a negative impact on the natural disease outcome and immune response of HCV infection,
whereas the reverse remains unclear. We evaluated the impact of HCV co-infection on recovery of CD4+ and CD8+
T-cells and liver enzyme levels before and after initiation of highly active antiretroviral therapy (HAART) in HIV/HCV
co-infected patients.
Methods: A hospital-based, observational, prospective cohort study design was used for this study. Pre-
antiretroviral treatment (Pre-ART) and under HAART HIV mono-infected and HCV/HIV co-infected individuals who
are under regular follow-up were recruited for this study. 387 blood samples were collected from volunteer, known
HIV positive Ethiopian patients and screened for HCV. Twenty five HCV/HIV co-infected patients were prospectively
followed for four years. CD4+ and CD8+ T-cells and liver enzyme levels were determined annually for each of the
participant.
Results: The prevalence of HCV/HIV co-infection in this study was 6.5%. Both HCV/HIV co-infected and HIV mono-
infected under HAART groups showed CD4+ recovery (343 Vs 426; P < 0.004, OR = 4.97, 95% CI = 2.41 to 10.27)
respectively; but, the recovery rate was higher in mono-infected (80 Vs 426) than co-infected group (148 Vs 343).
The recovery and/or decline pattern of CD8+ T-cells was the same with that of CD4+. In 75% of co-infected groups,
the mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were above the upper limit of
normal reference range. Analyses restricted to individuals who initiated HAART and pre-ART showed similar results.
Conclusion: We found that CD4+ T-cell recovery was negatively affected by the presence of ongoing HCV
replication in under HAART co-infected individuals and fast decline of CD4+ T-cells in pre-ART patients. It was also
associated with increased ALT and AST enzyme levels in both HAART initiated and treatment naïve co-infected
patients.
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Figure 1 Sex distribution of study subjects in each group at
Yekatit-12 and Zenbaba General Hospitals, Addis Ababa
(Sep. 2006- Nov. 2010).
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Hepatitis C virus (HCV) is a RNA virus which has been
known to cause acute and chronic necroinflamatory dis-
ease of the liver. It infects more than 170 million people
worldwide. In Western countries, HCV is the leading
cause of end-stage liver disease and hepatocellular
carcinoma, as well as the main indication for liver trans-
plantation [1,2]. Because of shared routes of transmis-
sion, co-infection with HCV and HIV is quite common.
In the era of HAART, HCV-related liver disease has
emerged as a significant cause of morbidity and mortal-
ity due to the increased risk for hepatotoxicity of
HAART and likelihood of onset of an AIDS-defining
illness [3].
Both innate and Cell-mediated immune responses are
crucial in the early control of viral infections. Although
the role of T-cell immunity during acute and chronic
HCV infection and its relationship with HCV replication
remains controversial, CD4+ T-cell responses particu-
larly to non-structural HCV proteins, specific CD8+
T cell cytolytic action, and high level local gamma-
interferon production are believed to be important [4]. It
has been suggested that the deficiency of cell-mediated
immune response against HIV infection actually favors
the chronic development of acute HCV infection and
also the progression of chronic hepatitis to cirrhosis [5].
HCV/ HIV co-infection often associated with elevated
liver biochemical enzymes such as alanine aminotrans-
ferase, aspartate aminotransferase and alkaline phosphat-
ase [6].
Although the co-infection of HIV with HCV has been
recognized worldwide in individuals exposed to blood
borne diseases, limited data are available on the extent
of co-infection, effect of these viruses on the immune
system and liver in developing countries. Ethiopia
belongs to the group of countries which are highly
endemic for viral hepatitis. Few studies have been done
on HIV/HCV co-infection prevalence in Ethiopia but the
knowledge about the interrelationship between these
viruses and their effect on the immune system remains
unclear [7].
Therefore, the aim of this study was to estimate the
prevalence of HCV sero-positivity in a cohort of people
living with HIV in Addis Ababa and to investigate its
effect on the recovery of CD4+ and CD8+ T-lymphocytes
and liver enzymes in the era of HAART and before
HAART in Ethiopia.
Methods
Study design, population and sampling technique
A hospital-based, observational, prospective cohort
study design was used for this study. The study popula-
tion was comprised of HIV patients on follow-up and
VCT attendants at Yekatit-12 and Zenbaba GeneralHospitals in September 2006, Addis Ababa, Ethiopia.
From September 1–30, 2006, a total of 387 HIV positive
patients were screened for HCV and HBV. Hence, a
convenient, non-probability sampling technique was
employed and no scientific method were used to calcu-
late the sample size, instead, we screened all eligible
patients who visited the two hospitals during the month
September 2006 and we followed volunteer 25 HCV/
HIV co-infected patients. The control groups (HCV neg-
atives) were also screened for HBV infection.
All those 25 HCV/HIV co-infected and 25 HIV mono-
infected patients were enrolled in this hospital-based
observational follow-up study. All selected patients were
paired on the basis of world health organization (WHO)
clinical disease stages (All were WHO stage II patients).
The study groups were prospectively followed for four
years from Sep 2006 to Nov 2010 in order to determine
the impact of HCV/HIV co-infection on immunological
and liver enzyme levels of HIV patients.Patient grouping
Selected study cohort participants were arranged in to
four groups based on their HCV and HAART (status: I)
16 under HAART patients only with HIV infection
(Group 1), II) 16 HCV/HIV co-infected patients receiving
HAART (Group 2), III) 9 HIV positive pre-ART patients
without HCV infection (Group 3) and IV) 9 HIV/HCV
co-infected pre-ART patients (Group 4). Both co-infected
and HIV mono-infected under HAART patients has
been taking the same combination therapy (Zidovudine
(ZDV) + Lamivudine (3TC) + Efavirenz) and there were
no considerable difference on the duration of treatment
initiation between co-infected and HIV mono-infected
groups (8 and 7 months) respectively. Annual immuno-
logical and clinical chemistry tests were done only for
selected patient. The study subjects were also screened for






























Figure 2 Sex distribution of HCV/HIV co-infected study subjects
with age interval at Yekatit-12 and Zenbaba General Hospitals,
Addis Ababa (Sep. 2006- Nov. 2010).
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Flavicheck-HCV, a commercial fourth generation, rapid,
qualitative, two-site sandwich immunoassay test device
(Qualpro Diagnostics, 88/89, phase IIC, Verma Industrial
Estate, Verna, Goa-403 722, India, 2004) was employed
according to the manufacturer’s instructions. It detects
total antibodies specific to HCV in serum or plasma. It
uses a multi-epitope recombinant peptide antigen that is
broadly cross-reactive to all major HCV genotypes.
Except the recombinant peptide inserted the principle,
procedure and interpretation of HBV are the same with
that of HCV.
CD4+ and CD8+ T-cells Enumeration
CD4+ and CD8+ T-cell counts were enumerated for each
patient annually for four consecutive years starting from
Sep 2006 through Nov 2010. Both tests were measured
by standard 3-color flow cytometry using Fluorescent
Activated Cell Sorter (FACscan) machine (Becton
Dickinson Biosciences, San Jose, CA 95131–1807, USA).
No viral load test was performed for all groups of
patients because of scarcity of resources.
Measurement of GPT and GOT
Humastar180, chemistry analyzer (Human GmbH.65205
Wiesbaden, Germany) was used to measure the liverTable 1 Mean baseline and fourth year CD4+ and CD8+ cell co
Cells/μl Year HIV/HCV co-infected (G2) (n = 16) Mean ± S
CD4+ 1st year 148 ± 30
4th year 343 ± 119
CD8+ 1st year 1104 ± 420
4th year 1259 ± 430
(Number of patients in parenthesis), N/S- not significant.
Key: G = Group, HAART = highly active antiretroviral therapy, ART = Antiretroviral tre
SD = standard deviation.enzyme levels (serum GPT, GOT and ALP). Principle
of operation is based on the fact that substances of
clinical interest selectively absorb or emit energy (light)
at different wavelengths.
Statistical analysis
Data entry and analysis was done using computer soft-
ware SPSS version 16. Data was summarized and
presented in a descriptive measure such as a table,
figures and line graphs. Group comparisons were done
using logistic regression, hazard ratio (HR) and odds
ratio (OR) to determine the independent effect of the
variables by calculating the strength of the association
between the infection and risks. Line graph was done to
show the trends of CD4+ and CD8+ T cells counts and
liver enzyme levels along the four years follow up.
Kaplan-Meier survival analysis done to predict the
survival time of HCV/HIV co-infected patients from
diagnosis of AIDS to termination of the study. P-value of
less than 0.05 was considered statistically significant.
The study protocol was approved by Addis Ababa
University, biology department research ethics commit-
tee. All participants gave informed and written consent,
and HCV-positive cases were contacted with nurses and
doctors for further management.
Result
Prevalence of HCV/HIV among the study subjects
The total prevalence of HCV among the 387 HIV
patients (182 female and 205 male) who visited the two
hospitals in the month September 2006 and were
screened for the study was 6.5%. Of these, 206 (53.23%)
were under HAART and 181 (46.77%) pre-ART patients.
Relatively more HCV infected patients, (7.8%), were
from those under HAART and (5%) from pre-ART. The
mean age for the patients under investigation was
38.9 years. Even though it was not statistically significant
(p = 0.06), females were relatively younger (34.5 years)
when compared to males (42.6 years). The mean age of
patients in the four groups (1–4) was comparable; 41.2,
41.3, 46.2 and 40.2 years respectively, indicating there
were no a statistical age differences across the groups
(p = 0.09). There were also no statistical differenceunt of under HAART subjects
D HIV mono-infected (G1) (n = 16) Mean ± SD p value
80 ± 151 P < 0.002
426 ± 113 P < 0.004
950 ± 631 P < 0.003
1247 ± 420 N/S






























































Figure 3 Line graphs showing trends of CD4+ (A), CD8+ (B) and GPT (C) respectively along the 4 years in all groups of patients.
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ages of the study subjects (38.9 Vs 41.2, 41.3, 46.2 and
40.2). As shown in Figures 1 and 2, 23 (92%) of the total
co-infected patients fall between 20–49, 1 (4%) between
50–59 and 1 (4%) above 60 years of age. In this study,
HCV/HIV co-infection was higher in males than females
(60% Vs 40%, p = 0.06). Furthermore, 11(73.33%) of the
co-infected males were over the age of 40 years.
Table 1 and Figure 3A-B shows the mean baseline and
fourth year CD4+ and CD8+ cell count of HIV/HCV co-
infected and HIV mono-infected under HAART pa-
tients. The CD4+ and CD8+ recovery of co-infected
group 2 was impaired by the co-infection of HCVTable 2 Mean baseline and fourth year CD4+ and CD8+ cell co
Cells/μl Year HIV/HCV co-infected (G4) (n = 9) Mean ± S
CD4+ 1st year 303 ± 73
4th year 211 ± 163
CD8+ 1st year 1612 ± 380
4th year 772 ± 552
(Number of patients in parenthesis), N/S- not significant.
Key: G = Group, HAART = highly active antiretroviral therapy, ART = Antiretroviral tre
SD = standard deviation.despite the presence of HAART (CD4+: 148 Vs 343;
P < 0.003 and CD8+: 1104 Vs 1259; P < 0.004) at the
baseline and the last (fourth year). However, in HIV
mono-infected group 1 both variables recovered signifi-
cantly (CD4+: 80 Vs 426; p < 0.000 and CD8+: 950 Vs
1247; P < 0.003). Even though both groups showed
recovery during the last CD4+ count; however, the
recovery rate was high in mono-infected group 1 than
co-infected group 2 (426 Vs 343; P < 0.004, OR = 4.97,
95%CI = 2.41 to 10.27).
Table 2 and Figure 3A-B shows the mean baseline and
fourth year CD4+ and CD8+ cell count of HIV/HCV co-
infected and HIV mono-infected pre-ART individuals.unt of pre-ART subjects
D HIV mono-infected (G3) (n = 9) Mean ± SD p value
435 ± 52 P < 0.003
314 ± 27 P < 0.004
1676 ± 343 N/S
1092 ± 177 P < 0.002
atment, μl = microliter, CD = Cluster designation/differentiation,
Table 3 Mean baseline and fourth year CD4+ and CD8+ cell count of HIV/HCV co-infected under HAART and
pre-ART patients
Cells/μl Year HIV/HCV co-infected (G2) under HAART (n = 16) Mean ± SD HIV mono-infected (G4) pre-ART (n = 9) Mean ± SD p value
CD4+ 1st year 148 ± 30 303 ± 73 P < 0.001
4th year 343 ± 119 211 ± 163 P < 0.004
CD8+ 1st year 1104 ± 420 1612 ± 380 P < 0.003
4th year 1259 ± 430 772 ± 552 P < 0.003
(Number of patients in parenthesis), N/S- not significant.
Key: G = Group, HAART = highly active antiretroviral therapy, ART = Antiretroviral treatment, μl = microliter, CD = Cluster designation/differentiation,
SD = standard deviation.
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difference between co-infected and HIV mono-infected
groups (303Vs 435; P < 0.003) whereas, both groups had
a comparable CD8+ count (1612 Vs 1676) respectively.
The last cell count (fourth year) clearly indicated that
HCV co-infection was associated with fast decline of
both CD4+ and CD8+ cells count than HIV mono-
infected groups (CD4+: 211 Vs 314; P < 0.004 and CD8+:
772 Vs 1092; P < 0.002) respectively.
Table 3 shows the mean CD4+ and CD8+ counts of
both co-infected groups of patients at the beginning and
fourth year. In the pre-ART group (G4), both CD4+ and
CD8+ count were declined to initiate HAART (303 to
211, P < 0.004 and 1612 to 772, P < 0.001) respectively,
whereas, in the HAART group (G2) both cells recovered
even though the rate of recovery was impaired by the
presence of HCV (CD4+: 148 Vs 343; P < 0.003 and CD8
+: 1104 Vs 1259; P < 0.004) respectively.
The survival analysis curve shows that, HCV/HIV co-
infected patients experienced significantly decreased
durations of survival from the time of AIDS diagnosis
(hazard ratio (HR), 2.85; 95% CI, 1.16-3.13) (Figure 4).
The use of HAART improved survival duration (HR,
0.31; 95% CI, 0.11-0.37). HCV/HIV co-infected patients
also experienced shorter durations of survival from the
date of diagnosis of HIV infection to AIDS diagnosis
than did HIV mono-infected patients (HR, 3.82; 95% CI,
1.32- 4.23) (Figure 5).Figure 4 Survival curve for time from diagnosis of AIDS to
termination of the study, stratified by HCV co-infection status,
CD4+ cell count and HAART use.Table 4 shows liver enzyme levels of both co-infected
under HAART and pre-ART patients at the beginning
and fourth year sampling result. It shows a decline to
the normal reference values from baseline to the fourth
year which indicates the improvement of hepatotoxicity.
The pre-ART co-infected group 4 patients improved
better (246 IU/L to 46 IU/L) in GPT level than
under HAART co-infected group patients (35 IU/L to
33 IU/L). The mean liver enzyme levels of group 1 and
group 3 were generally fall within the normal reference
range. However, the two co-infected groups had slightly
greater than the normal range (Figure 3C and Table 4).Discussion
Hepatitis C virus infection is one of the major diseases
of mankind and is a serious global public health prob-
lem. The precise effect of HCV co-infection on the re-
covery of immune cells and liver enzymes in HIV
patients before and after HAART remains controversial.
However, a number of studies have suggested that the
presence of HIV infection accelerates the course of
HCV-related liver disease in HCV/HIV co-infected pa-
tients [5,8]. HIV is known to impair T-helper type 1 im-
mune response which in turn alters the response of
immune cells to HCV. This permits greater HCV repli-
cation and consequently, greater infection and injury to
hepatocytes which leads to more rapid progression toFigure 5 Hazard curve for HCV/HIV co-infected and HIV mono-
infected patients, stratified by HCV co-infection status, CD4+
cell count and HAART use.
Table 4 Mean baseline and fourth year liver enzyme levels of HIV/HCV co-infected under HAART and pre-ART patients
Enzyme level
(IU/l)
Year Under HAART co-infected Group (G2)
(n = 16), Mean ± SD
Pre-ART Co-infected group (G4)
(n = 9), Mean ± SD
p value
GPT 1st year 35 ± 5 246 ± 22 P < 0.000
4th year 33 ± 12 46 ± 10 N/S
GOT 1st year 32 ± 5 207 ± 12 P < 0.000
4th year 36 ± 14 35 ± 14 N/S
ALP 1st year 243 ± 50 239 ± 93 N/S
4th year 235 ± 124 207 ± 85 N/S
(Number of patients in parenthesis), N/S- not significant.
Key: GPT = Glutamate pyruvate transaminase, GOT = Glutamate oxaloacetate transaminase, ALP = Alkaline phosphatase, IU = International unit, l = liter.
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tocellular carcinoma) [5].
Given the above interaction of the two viruses and their
implications on the proper management of the co-infected
cases, the aim of this work was to describe the prevalence
of HCV co-infection among HIV patients at Yekatit-12 and
Zenbaba General Hospitals and assess the immunological
and clinical chemistry results over a four years period.
Results show that the prevalence of HCV among the 387
Addis Ababa resident-HIV patients, who visited the two
hospitals during one month (September 2006), was 6.5%.
This was low in accordance with the previous HIV/HCV
co-infection studies in Ethiopia by Workinesh, et al. [7] and
Addisu et al. [2] which was 8.6% and 10.5% respectively.
Compared to Spain (33%), U.S.A (30%), France (24.3%) and
Morocco (19.8%), the present prevalence was still low [5,9].
The co-infection prevalence in under HAART (7.8%) was
more than Pre-ART patients (5%). This might be due to
the higher numbers of under HAART (N = 206) than the
pre-ART (N= 181) patients. In this study, from the 25 co-
infected patients more males were co-infected than females
(60% Vs 40%). This might be due to the higher number of
males than females in the sample population, hence, does
not justify to saying that it is gender influenced.
The distribution of HCV/HIV co-infection, in Figure 2
shows the direct link of age to HCV prevalence. It starts
with 20% in age group 20–29 and grows to nearly 45% in
age groups 40–49 years suggesting an association with age.
A higher prevalence in older age groups could be a reflec-
tion due to the chronic nature of the disease, sexual behav-
ior or it may be related to hormone and immunity. Our
finding was in agreement with the work of Sugimoto, et al.
[11] that found HIV/HCV co-infection is higher in males
over 40 years of age. This is a serious indicator for over
50-80% of co-infected patients develop chronic infection
that gives rise to liver cirrhosis (4-20%) and hepatocellular
carcinoma in 1-5% [10].
The observation on immunological parameters over four
years showed that an improvement of CD4+ and CD8+
counts in both HCV positive and negative under HAART
patients. However, the CD4+ increase in those not co-infected with HCV was much better when compared with
those of HCV infected (426 ± 113 Vs 343 ± 119, P < 0.004).
This suggests that although HAART does improve the
immune system of HCV co-infected patients, its efficiency
is relatively compromised by HCV interactions (Figure 3
and Tables 1 and 2). Our finding was in agreement with
researchers who concluded that even though HAART
suppresses HIV and increase CD4+ count response, how-
ever, it is affected by the presence of HCV co-infection [4].
In addition, HAART adversely affect HCV outcomes by
increasing HCV viral load, hepatotoxicity and increased
HCV related liver disease progression in HIV/HCV co-
infected people [12].
Variety of factors is incriminated in influencing these
treatment outcomes. The factors include presence of high
HCV RNA load, low treatment responses of genotypes
1 and 4, high rate replication (1012 virions/day) and its ex-
ceptionally high mutation rate producing a genetic variety
[1]. Our result though does not have data on the influence
of viral interaction, has shown that the presence of HCV
decreases the efficiency of HAART when compare to those
that were negative for HCV, hence goes well with the
conclusions of Kedziora, et al. work [1]. The improvement
of the immune status with CD4+ and CD8+ counts on its
own improves survival of patients the minimum by slowing
viral load and elimination of infected cells.
In the present study, the liver enzyme levels were much
higher than the above limits of reference in co-infected
than HIV mono-infected patients. In supporting the
present study; DeSemone and his colleagues [13] found that
increased liver enzyme level often associated with HCV co-
infection. The mean GPT level of pre-ART co-infected
group 4 patients during 1st year was at least fivefold greater
than that of under HAART co-infected group 2 patients.
From 2nd year and onwards, both group 2 and group 4 had
comparatively increased levels of liver enzymes
(Figure 3 and Table 4). In this study, more than 70% of the
co-infected patients showed increased levels of GPT above
the limits of reference which agreed with the finding of
Lawson [14] in which only 30% of HCV patients have
normal GPT levels.
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HCV has been confirmed to be a risk factor associated
with a 3 to 5-fold chance of developing elevated transami-
nases during HAART, compared to HIV patients without
HCV which was compatible with the present study. How-
ever, the present work was incompatible with the study
done by Gatti, et al. [8] that showed the synergetic
mitochondrial damage by HCV and HAART (especially
nucleoside analogs) were responsible for elevation of GPT
in HAART groups. In addition, the higher enzyme level in
the co-infected pre-ART group in this study indicates that
the effect of HCV is more pronounced in pre-ART era
than in the era of HAART. Furthermore, the HIV mono-
infected group 1 and group 3 had normal amount enzyme
levels throughout the follow up time. In supporting the
normal enzyme levels of HIV mono-infected group 1 and
group 3 in this study, Marina and Vincent [15] found that
HAART do not associated with increased liver enzymes.
The present study has several strengths. Although viral
load, HCV genotype and alcohol consumption status of
patients are crucial in clinical medicine however, CD4+
count is the main test routinely done to follow immune
recovery. The present study clearly showed the pattern of
CD4+ changes considering different factors during the
time of follow up. The information obtained in this study
may promote our understanding of the impact of HCV
infection on immunological parameters and liver enzyme
levels among HIV/HCV co-infected individuals. Viral load,
HCV genotype, alcohol consumption status and other
clinical information of patients were not done in this
study. Thus, with those limitations, we believe that this
cohort may provide an accurate reflection of current
clinical trends regarding this dual infection.Conclusion
The present study has shown that HCV infection has an
impact on the recovery of CD4+ and CD8+ cells of on
under HAART patients. The improvement in CD4+ cell
count of under HAART HIV/HCV co-infected subjects
were lower than the HIV mono-infected subjects and the
mono-infected patients responded better to HAART than
the co-infected patients. Moreover, HCV has a significant
association with higher liver enzyme level than CD4+ in
HIV/HCV co-infected patients. Because of the lower
prevalence rate of HIV/HCV co-infection reported from
previous few local studies in Ethiopia, the disease was
given less attention and seems forgotten at various levels
of health delivery institutions so that the significance of
the problem has been underestimated. Therefore, it is
advisable to make HCV-antibody screening for every HIV
infected individual prior to initiation of HAART. This will
in turn influence their clinical management as well as
outcome.Competing interests
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